All News

An all orally administered regimen containing Ninlaro, Revlimid and dexamethasone showed a 5.9-month improvement in progression-free survival compared with Revlimid and dexamethasone alone.

Never underestimate the power and inner strength of a hungry cancer patient.

A male breast cancer survivor recalls remarkable gifts of goodwill.

A breast cancer survivor wonders when it will be “safe” to toss the chemo wig and reflects about going down the road as a cancer survivor.

All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib).

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

My letter to Ty, a young man taken before his time.

Here are some important tips for cancer patients and caregivers to reduce stress, take care of themselves and enjoy the season.

I will never forget the emotions

The agent was approved as a treatment for patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).

The FDA's decision was based on two studies that measured the 30-day survival rate of adult and pediatric patients who had either overdosed on treatment or were experiencing early-onset toxicities.

Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.

I have stage 4 lung cancer. Here are 24 other things about me.

"We now finally have evidence that bone-targeted treatment is not only successful in treating bony metastases and preventing treatment-induced bone loss," said Michael Gnant.

The Screen This Too! campaign, created by the Colon Cancer Alliance, expands the awareness and prevention conversation. Simple in concept, broad in scope

A study released by the international nonprofit Cancer Support Community found that more than half of patients with cancer feel unprepared to discuss treatment options with their medical team, a significant finding given the high burden patients with cancer carry across a number of dimensions.

Cancer Support Community tackles the CLL experience in new cancer experience registry.

A study by the Cancer Support Community examined the factors that are most influential when patients choose a particular treatment option.

Unitio, Inc., a Boston based nonprofit organization and The Leukemia & Lymphoma Society (LLS) today announced a partnership to develop an online patient community that will bring together those affected by blood cancers to share real world experiences and contribute to vital research.

CancerCare, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, is pleased to announce the availability of co-payment assistance for pancreatic cancer patients through the CancerCare Co-Payment Assistance Foundation.

Debbie's Dream Foundation: Curing Stomach Cancer (DDF), an international non-profit organization that raises awareness and funds for stomach cancer, launched two research grants totaling $200,000 for the 2015-2016 grant cycle. A Career Development Award for $150,000 and a Young Fellowship Grant for $50,000 are included in the grants offered.

In 2007, Zoila Pasos found a lump in her breast when she was just a few weeks pregnant. Not long into the pregnancy, she miscarried. While she allowed her body time to heal, she had the lump checked and was told it was a benign cyst and nothing to worry about.

After a median follow-up of 10 months, the overall response rate in patients with PD-L1-expressing metastatic breast cancer was 33.3 percent.

It's amazing how we feel the need to apologize. We want to make others comfortable. Sometimes it just doesn't work.

Sadly, we cancer survivors are often measured by what we’ve lost to cancer. I would like to put something back in the space left by all the things taken away.

The DigniCap Cooling System reduces the severity and frequency of hair loss in patients receiving chemotherapy for breast cancer.

The addition of the PD-1 inhibitor Keytruda (pembrolizumab) to an established multiple myeloma regimen elicited responses in 76 percent of 17 patients with relapsed/refractory disease.

Millions of people worldwide hear these words every year.

Exactly one month after an oncologist told her that there was an 80 percent chance she was free of colon cancer, Taylor Arnold sat in front of a panel of patients, survivors and doctors, wondering why she was there.

In updated data from a phase 3 study, the addition of Empliciti reduced the risk of progression or death by 27 percent.